Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Ocuphire Pharma, Inc. Common Stock (OCUP)

Pharmaceutical Preparations

https://www.ocuphire.com

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

37000 GRAND RIVER AVE., SUITE 120
FARMINGTON HILLS, MI

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/06/2020

Market Cap

33,795,936

Shares Outstanding

24,060,000

Weighted SO

24,058,725

Total Employees

N/A

Upcoming Earnings

03/22/2013

Similar Tickers

RVPH --.--%

PLX --.--%

EYPT --.--%

SLS --.--%

RVPHW --.--%

EYEN --.--%

CGTX --.--%

RNAZ --.--%

KOD --.--%

Beta

0.3480

Last Div

0.0000

Range

1.16-4.5

Chg

0.0500

Avg Vol

147695

Mkt Cap

33795936

Exch

NASDAQ

Country

US

Phone

248 681 9815

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

2.0546

EV Multiple

0.5050

P/FV

0.8199

Div Yield %

0.0000

P/E

-2.3621

PEG

-0.1977

Payout

0.0000

Current Ratio

10.6798

Quick Ratio

10.6798

Cash Ratio

9.8640

DSO

51.1697

DIO

0.0000

Op Cycle

51.1697

DPO

48.6871

CCC

2.4825

Gross Margin

0.7110

Op Margin

-0.9167

Pretax Margin

-0.8568

Net Margin

-0.8575

Eff Tax Rate

0.0012

ROA

-0.3146

ROE

-0.3019

ROCE

-0.3711

NI/EBT

1.0009

EBT/EBIT

0.9346

EBIT/Rev

-0.9167

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

0.0000

CF/Debt

0.0000

Equity Multi

1.1033

Rec Turnover

7.1331

Pay Turnover

7.4968

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.3669

OCF/Share

-0.4438

FCF/Share

-0.4438

Cash/Share

1.6035

OCF/Sales

-0.6969

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.8199

P/B

0.8199

P/S

2.0546

P/E

-2.3621

P/FCF

-2.9483

P/OCF

-2.9065

P/CF

-2.9065

PEG

-0.1977

P/S

2.0546

EV Multiple

0.5050

P/FV

0.8199

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 06, 00:43 UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia GlobeNewswire Inc. Nov 27, 16:38 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 27, 16:38 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 01, 16:52 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Revenue Product Segmentation